Optos, a pioneering player in the Health Care industry, is renowned for its sophisticated retinal imaging technology. Established in 1992 by Douglas Anderson, following a personal tragedy where his son suffered blindness due to a missed diagnosis during a standard eye exam, the company has revolutionized how eye care professionals diagnose and manage retinal conditions.
The company's flagship product, optomap®, delivers high-resolution ultra-widefield images, capturing up to 200° of the retina in a single, comfortable scan. Recent advancements include the integration of Optical Coherence Tomography (OCT) with their imaging systems, enhancing early detection and management of conditions like glaucoma and diabetic retinopathy.
Headquartered in the United Kingdom, Optos is a division of Nikon Co. Ltd, Japan since 2015. They last received a grant investment from NHS England in September 2020, positioning themselves as a critical partner in comprehensive patient care. With nearly 30 years in operation, Optos continues to leverage its extensive clinical validation to expand its impact in global eye care.